Overview

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Status:
Recruiting

Trial end date:
2023-09-01

Target enrollment:

Participant gender:

Summary

Single arm multicenter phase II trial evaluating the role of Pembrolizumab in combination to Carboplatin-Paclitaxel chemotherapy in locally advanced cervical cancer patients.

Phase:

Phase 2

Details

Lead Sponsor:

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel
Pembrolizumab